Research programme: cancer radiopharmaceuticals - Centre for Probe Discovery and Commercialisation
Latest Information Update: 11 Jan 2017
At a glance
- Originator Centre for Probe Development and Commercialization
- Developer Centre for Probe Development and Commercialization; Janssen Biotech
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer